A 52-Week, Multicenter, Open-Label Study to Evaluate the Efffectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole Intramuscular Depot Program in Schizophren